Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target

The benefits of novel oral anticoagulants are hampered by bleeding. Since coagulation factor IX (fIX) lies upstream of fX in the coagulation cascade, and intermediate levels have been associated with reduced incidence of thrombotic events, we evaluated the viability of fIXa as an antithrombotic target. We applied translational pharmacokinetics/pharmacodynamics (PK/PD) principles to predict the therapeutic window (TW) associated with a selective small molecule inhibitor (SMi) of fIXa, compound 1 (CPD1, rat fIXa inhibition constant (Ki, 21 nmol/L) relative to clinically relevant exposures of apixaban (rat fXa Ki 4.3 nmol/L). Concentrations encompassing the minimal clinical plasma concentration (Cmin) of the 5 mg twice daily (BID) dose of apixaban were tested in rat arteriovenous shunt (AVS/thrombosis) and cuticle bleeding time (CBT) models. An Imax and a linear model were used to fit clot weight (CW) and CBT. The following differences in biology were observed: (1) antithrombotic activity and bleeding increased in parallel for apixaban, but to a lesser extent for CPD1 and (2) antithrombotic activity occurred at high (>99%) enzyme occupancy (EO) for fXa or moderate (>65% EO) for fIXa. translational PK/PD analysis indicated that noninferiority was observed for concentrations of CPD1 that provided between 86% and 96% EO and that superior TW existed between 86% and 90% EO. These findings were confirmed in a study comparing short interfering (si)RNA‐mediated knockdown (KD) modulation of fIX and fX mRNA. In summary, using principles of translational biology to relate preclinical markers of efficacy and safety to clinical doses of apixaban, we found that modulation of fIXa can be superior to apixaban.

[1]  R. Bentley,et al.  Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability , 2015, Thrombosis and Haemostasis.

[2]  Marian E. Gindy,et al.  Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit , 2015, Molecular therapy. Nucleic acids.

[3]  M. Kay,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[4]  R. Becker,et al.  Factor IXa as a target for anticoagulation in thrombotic disorders and conditions. , 2014, Drug discovery today.

[5]  S. Bartz,et al.  Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension , 2014, Hypertension Research.

[6]  M. Streiff,et al.  The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery , 2013, Expert review of hematology.

[7]  Yafei Ji,et al.  Alternate Synthesis of Apixaban (BMS-562247), an Inhibitor of Blood Coagulation Factor Xa , 2013 .

[8]  R. Becker,et al.  Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. , 2011, Cardiovascular therapeutics.

[9]  S. Bartz,et al.  siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids[S] , 2011, Journal of Lipid Research.

[10]  T. Leil,et al.  Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose , 2010, Clinical pharmacology and therapeutics.

[11]  B. Xin,et al.  Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis , 2010, Journal of cardiovascular pharmacology.

[12]  J. Eikelboom,et al.  Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism , 2010, Arteriosclerosis, Thrombosis and Vascular Biology.

[13]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[14]  E. Crain,et al.  Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits , 2009, Journal of thrombosis and haemostasis : JTH.

[15]  S. Darby,et al.  Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. , 2007, Blood.

[16]  Thomas Orfeo,et al.  The Significance of Circulating Factor IXa in Blood* , 2004, Journal of Biological Chemistry.

[17]  F. Rosendaal,et al.  Decreased mortality of ischaemic heart disease among carriers of haemophilia , 2003, The Lancet.

[18]  P. Carmeliet,et al.  Blood Coagulation Factor X Deficiency Causes Partial Embryonic Lethality and Fatal Neonatal Bleeding in Mice , 2000, Thrombosis and Haemostasis.

[19]  N. Maeda,et al.  A coagulation factor IX-deficient mouse model for human hemophilia B. , 1997, Blood.

[20]  M. Zoppè,et al.  A factor IX-deficient mouse model for hemophilia B gene therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. D. Brown.  American Society for Pharmacology and Experimental Therapeutics , 1927, Science.

[22]  N. Albert.  Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. , 2014, Heart & lung : the journal of critical care.

[23]  Experimental Therapeutics.  Pharmacology research & perspectives , 2013 .

[24]  D. Xavier,et al.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[25]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[26]  W. Funkhouser,et al.  In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. , 2007, Thrombosis research.

[27]  [Decreased mortality]. , 1950, Nordisk medicin.